Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the purpose of the study and have provided written consent to participate
• People aged 18 years or older
• People who have been diagnosed with mantle cell lymphoma (a type of blood cancer) that has come back or stopped responding to treatment, confirmed by a tissue or cell sample
• People whose mantle cell lymphoma returned or stopped responding after standard first-line chemotherapy, and who have received at least one previous treatment that included a drug called ibrutinib
• People who previously received a drug called bendamustine, where that treatment kept the disease under control for more than one year
• People who have at least one measurable lymph node or tumour mass that can be tracked during the study
• People with a life expectancy of at least 24 weeks (roughly six months)
• People with a general health and activity level rated 0 to 2 on a standard medical scale (meaning able to carry out daily activities with no more than moderate limitations) (confirm with trial site)
• People with adequate blood, kidney, and liver function — or whose results are below normal only because of the underlying disease itself

Who may not be able to join:

• People with a history of severe allergic or life-threatening reactions to certain types of antibody-based medicines, or known sensitivity to the drugs bendamustine or rituximab
• People for whom the study drugs polatuzumab, bendamustine, or rituximab are medically unsuitable
• People who have received certain antibody-based treatments within four weeks or five half-lives before the study starts
• People who have taken part in another clinical trial using an experimental drug within 28 days before starting this study
• People who have had another cancer (other than certain skin cancers or a specific type of cervical pre-cancer) within the last three years
• People who have received radiotherapy, chemotherapy, immunotherapy, or other cancer treatments within two weeks before the study starts
• People who have had major surgery or a serious injury within 28 days before the first study dose
• People who are currently taking corticosteroid medicines (such as prednisone) at doses above 30 mg per day for reasons unrelated to lymphoma symptoms
• People who had an autologous stem cell transplant (a procedure using their own stem cells) within 100 days before the study starts
• People who have previously had an allogeneic stem cell transplant (using stem cells from a donor)
• People who are considered eligible for an autologous stem cell transplant
• People whose lymphoma has spread to the brain or spinal cord
• People who currently have moderate or severe nerve damage (such as numbness, tingling, or pain in the hands or feet) rated above Grade 1
• People with serious uncontrolled health conditions, including significant heart disease (such as a heart attack in the past six months, unstable heart rhythm, or severe heart failure) or significant lung disease
• People with an active infection at the time of enrolment, or who have been hospitalised or needed intravenous antibiotics for an infection within four weeks before the study starts
• People with suspected or inactive (latent) tuberculosis
• People who test positive for chronic hepatitis B or hepatitis C
• People known to be living with HIV or HTLV-1 (a virus affecting the immune system)
• People who are pregnant, breastfeeding, or planning to become pregnant within one year of the last study dose
• Women who could potentially become pregnant and are unwilling or unable to use adequate contraception from the start of the study until the last dose
• Women who could potentially become pregnant and who have a positive pregnancy test at screening, or whose pregnancy test was not performed within seven days before the first study treatment
• Male participants who are unwilling or unable to use adequate contraception methods during the study
• People whose routine blood test results show abnormal kidney, liver, or blood clotting function

Important: Always verify eligibility with the trial site directly before applying.